

Vered Caplan, Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C2-026

## **THINKING INSIDE THE BOX: CENTRALIZED VS DECENTRALIZED MANUFACTURING**

**Vered Caplan**

Orgenesis Inc., Israel

Cell therapy refers to the injection of cells to cure various diseases. Cell therapy is a rapidly growing field in medicine that can aim to treat different diseases such as diabetes, liver diseases, immuno-oncology, cardiology, dermatology and autoimmune disease. The cell therapy industry needs to overcome major challenges before the developed therapies can be brought to patients worldwide. There is a high demand to satisfy patient needs and the manufacturing technology lacks the capacity to meet this urgency. In addition, there is currently a tremendous burden of cost associated with cell and gene therapies like CART, because these treatments are being manufactured at offsite CMOs. Finally, the regulatory process is long, expensive and complicated. There is a great need for a custom-made approach that is tailored to the specific requirements of clients and designed to ensure short lead times with competitive costs, in order to bring state of the art therapies to the market. Orgenesis is establishing a one-stop-shop point of care service for hospitals to bring these therapies in a cost effective, high quality and scalable manner to patients. The organization is leveraging IP, technical expertise and know-how. The platform allows a modular cell production cGMP closed system platform for the development of early stage products. Author's vision is providing the pathway for cell and gene therapies to cure disease, by furthering the research and development of technologies throughout the world.

## **BIOGRAPHY**

Vered Caplan was the Chief Executive Officer of Orgenesis Inc. since August 14, 2014. She has an MSc in Biomedical Engineering from Tel-Aviv University specializing in Signal Processing; Management for Engineers from Tel-Aviv University specializing in Business Development and a BSc in Mechanical Engineering from the Technion-Israel Institute of Technology specialized in software and CAD systems. Throughout her managerial career, she served as CEO of several biotechnology such as: Interim (President and CEO), since 2008, she was Chief Executive Officer of Kamedis Ltd., From 2004 to 2007, she was Chief Executive Officer of GammaCan International Inc., During the previous five years, she has been a director of the following companies: Optical Ltd., Inmotion Ltd., Nehora Photonics Ltd., Ocure Ltd., Eve Medical Ltd., and Biotech Investment Corp.

[vered.c@orgenesis.com](mailto:vered.c@orgenesis.com)



Note: